The authors of the study from two higher educational institutions and two institutes of the Russian Academy of Sciences have developed a new class of antibiotics that can effectively combat methicillin-resistant Staphylococcus aureus. This was reported by the press service of the Moscow Institute of Physics and Technology (MIPT).
The drug candidate BX-SI043 demonstrated good results in toxicological tests on both cells and animals. In addition to strong antibacterial activity, it showed a high selectivity index, which means that the antibiotic acts purposefully on bacterial cells and is low-toxic to animal and human cells.
Staphylococcus aureus is a bacterium that causes many dangerous diseases, such as skin infection, pneumonia, and bloodstream infections. Treatment of diseases is becoming increasingly difficult as more resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) appear.
According to the authors of the study, now, thanks to the presence of two functional groups in the developed antibiotics, there is reason to assume a hybrid mechanism of action. This will allow successful combating of diseases.
The study lasted two years. In our article, we describe the synthesis of an original library of 22 triazenoindoles with high activity against a wide range of clinical isolates of multidrug-resistant methicillin-resistant Staphylococcus aureus.
The authors of the study are employees of MIPT, the I.M. Sechenov Moscow State Medical University of the Ministry of Health of the Russian Federation, the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, and the A.N. Severtsov Institute of Ecology and Evolution of the Russian Academy of Sciences. The results of the study can be found in the authoritative scientific journal International Journal of Molecular Sciences.
Related materials:
Trials of a drug for the treatment of Duchenne disease have begun in Russia